Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Moderna said it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

STAFF WRITERS GIPPSLANDERS are being urged to protect themselves and their loved ones against flu and respiratory syncytial ...

In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

The respiratory syncytial virus (RSV) vaccine, introduced across the UK in late summer 2024, led to a 72% reduction in babies hospitalised with the virus if mothers were vaccinated, a new study has ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...